Skip to main content Accessibility help
×
Home

High rate of linezolid intermediate susceptibility and resistance among enteric vancomycin-resistant Enterococcus (VRE) recovered from hospitalized patients actively screened for VRE colonization

  • Thomas J. Dilworth (a1), Eric T. Beck (a2), Rachel A. Pedersen (a3), Waseem G. Al-Karkokly (a2), Margaret M. Cook (a1), Erika K. Aldag (a1), David J. Kramer (a4), Ajay K. Sahajpal (a3), Iram Nadeem (a5), Brian P. Buggy (a5) and Charles F. Brummitt (a5)...

Copyright

Corresponding author

Author for correspondence: Thomas J. Dilworth, Email: thomas.dilworth@aurora.org

Footnotes

Hide All

PREVIOUS PRESENTATION. This work was presented as poster no. 1225 at IDWeek 2018 on October 5, 2018, in San Francisco, California.

Footnotes

References

Hide All
1. Reyes, K, Bardossy, AC, Zervos, M. Vancomycin-resistant enterococci: epidemiology, infection prevention, and control. Infect Dis Clin North Am 2016;30:953965.
2. Kelesidis, T, Humphries, R, Uslan, DZ, Pegues, DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;5 2:228234.
3. Bi, R, Qin, T, Fan, W, Ma, P, Gu, B. The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist 2018;13:1119.
4. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. CLSI supplement M100. Wayne, PA: CLSI; 2018.
5. Bagga, B, Buckingham, S, Arnold, S, Nesbitt, A, Guimera, D, Lee, K. Increasing linezolid-resistant Enterococcus in a children’s hospital. Pediatr Infect Dis J 2018;37:242244.
6. Clinical Laboratory Standards Institute. Ad hoc working group to reassess daptomycin breakpoint for enterococci. https://clsi.org/media/2307/2018_june_ast_bpwg_report_2__dapto_ceftaroline_cefiderocol.pdf. Published 2018. Accessed November 26, 2018.
7. Sader, HS, Farrell, DJ, Flamm, RK, Jones, RN. Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009–2013). J Glob Antimicrob Resist 2015;3:161165.
8. Pfaller, MA, Mendes, RE, Streit, JM, Hogan, PA, Flamm, RK. Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important gram-positive cocci in the United States from the LEADER Surveillance Program (2011–2015). Antimicrob Agents Chemother 2017;61:e0060917.
9. Cakirlar, FK, Samasti, M, Baris, I, et al. The epidemiological and molecular characterization of vancomycin-resistant enterococci isolated from rectal swab samples of hospitalized patients in Turkey. Clin Lab 2014;60:18071812.
10. Doern, CD, Park, JY, Gallegos, M, Alspaugh, D, Burnham, C-AD. Investigation of linezolid resistance in staphylococci and enterococci. J Clin Microbiol 2016;54:12891294.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed